AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3478732 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg PGE2 slow release hydrogel pessary
Number of subjects: 24
Study 3478732 — intervention group
Group type: COMPARATOR
Intervention: 3mg vaginal tablet (Upjohn)
Number of subjects: 24
Study 30249307 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour of continuous direct observation for hand hygiene opportunities (HHOs)
Number of subjects: 0
Study 28288767 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM oral paste (0.2 mg/kg)
Number of subjects: 64
Study 28288767 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM oral solution (0.2 mg/kg)
Number of subjects: 64
Study 28288767 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM IM solution (0.2 mg/kg)
Number of subjects: 64
Study 28288767 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 64
Study 27366506 — intervention group
Group type: EXPERIMENTAL
Intervention: BIPAP
Number of subjects: 80
Study 27366506 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow CPAP
Number of subjects: 80
Study 27366506 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow CPAP
Number of subjects: 80
Study 27366506 — intervention group
Group type: COMPARATOR
Intervention: Deep breathing exercises, respiratory physiotherapy and O2 therapy
Number of subjects: 80
Study 23931729 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Videoteleconferencing (CVT)
Number of subjects: 0
Study 23931729 — intervention group
Group type: COMPARATOR
Intervention: In-person delivery
Number of subjects: 0
Study 21128258 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 3 mg/kg
Number of subjects: 170
Study 21128258 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 10 mg/kg
Number of subjects: 170
Study 21128258 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 30/10 mg/kg
Number of subjects: 170
Study 21128258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 18204336 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 28
Study 18204336 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 28
Study 18204336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17036618 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron (12.5 mg)
Number of subjects: 100
Study 17036618 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (4 mg)
Number of subjects: 100
Study 12731691 — intervention group
Group type: EXPERIMENTAL
Intervention: Product A (without active ingredients)
Number of subjects: 76
Study 12731691 — intervention group
Group type: EXPERIMENTAL
Intervention: Product B (with active ingredients)
Number of subjects: 76
Study 10702816 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC dressing changes every 10 days (Group A)
Number of subjects: 399
Study 10702816 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC dressing changes every 5 days (Group A)
Number of subjects: 399
Study 10702816 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC dressing changes every 5 days (Group B)
Number of subjects: 399
Study 10702816 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC dressing changes every 2 days (Group B)
Number of subjects: 399
Study 10702816 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC dressing changes at longer intervals (10 days for Group A and 5 days for Group B)
Number of subjects: 399
Study 8779383 — intervention group
Group type: EXPERIMENTAL
Intervention: Test device comprising a Tuohy needle and clamp weighing 75.02 g applied to five vein sites (dorsum of arm, dorsum of hand, cephalic, ventrum of arm, cubital fossa)
Number of subjects: 167
Study 8779383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain expectations ranked by volunteers
Number of subjects: 167
Study 1649838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovine CRH infusion (1 microgram/kg.h)
Number of subjects: 10
Study 1649838 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (placebo)
Number of subjects: 10
Study 6304787 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolipram (3 mg per day)
Number of subjects: 10
Study 6304787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30975204 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface neuromuscular electrical stimulation (NMES)
Number of subjects: 30
Study 30975204 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastication apparatus (MA)
Number of subjects: 30
Study 30975204 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement oral appliance (OAm) with embedded thermosensitive microchip
Number of subjects: 30
Study 30975204 — intervention group
Group type: COMPARATOR
Intervention: Mandibular advancement oral appliance (OAm)
Number of subjects: 30
Study 29480527 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based training with weekly phone calls (n=232)
Number of subjects: 464
Study 29480527 — intervention group
Group type: COMPARATOR
Intervention: Educational control group with general positive parenting advice and one 45-minute phone call (n=232)
Number of subjects: 464
Study 27899456 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled smoked cannabis
Number of subjects: 126
Study 27899456 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled vaporized cannabis
Number of subjects: 126
Study 27899456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabis administration
Number of subjects: 126
Study 27899456 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation routes (smoked and vaporized)
Number of subjects: 126
Study 27899456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dosing
Number of subjects: 126
Study 27899456 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined THC ≥5 μg/L plus THCCOOH/11‐hydroxy‐THC ratio <20 cutoff
Number of subjects: 126
Study 24670413 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (angiotensin II receptor blocker)
Number of subjects: 82
Study 24670413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 22421246 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic technique
Number of subjects: 105
Study 22421246 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid‐palmar mini incision
Number of subjects: 105
Study 22421246 — intervention group
Group type: COMPARATOR
Intervention: Regular open incision
Number of subjects: 105
Study 22421246 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 105
Study 20065047 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B daily regimen (1 mg kg(‐1) day(‐1) for 15 days)
Number of subjects: 605
Study 20065047 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B alternate day regimen (1 mg kg(‐1) on alternate days for 15 days)
Number of subjects: 605
Study 18687174 — intervention group
Group type: EXPERIMENTAL
Intervention: HSH40
Number of subjects: 60
Study 18687174 — intervention group
Group type: COMPARATOR
Intervention: NS
Number of subjects: 60
Study 18687174 — intervention group
Group type: COMPARATOR
Intervention: HES
Number of subjects: 60
Study 15763053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) combined with Ginsenosides (GS)
Number of subjects: 80
Study 15763053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex)
Number of subjects: 80
Study 15763053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenosides (GS)
Number of subjects: 80
Study 15763053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 11926175 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus a detailed cognitive assessment (112 patients)
Number of subjects: 228
Study 11926175 — intervention group
Group type: COMPARATOR
Intervention: Routine care (116 patients)
Number of subjects: 228
Study 10102070 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy
Number of subjects: 145
Study 7565822 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal solution of apomorphine (10 or 15 mg)
Number of subjects: 5
Study 7565822 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin suppository (25 and 50 mg)
Number of subjects: 5
Study 7565822 — intervention group
Group type: EXPERIMENTAL
Intervention: Witepsol‐H15 suppository (50 and 100 mg)
Number of subjects: 5
Study 2225702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 50 mg daily for 2 weeks
Number of subjects: 13
Study 2225702 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin, 50 mg twice a day
Number of subjects: 13
Study 334221 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 0
Study 334221 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 0
Study 30643982 — intervention group
Group type: EXPERIMENTAL
Intervention: SK-1202 (26 g/day)
Number of subjects: 250
Study 30643982 — intervention group
Group type: EXPERIMENTAL
Intervention: SK-1202 (39 g/day)
Number of subjects: 250
Study 30643982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 28025352 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5 ml; 5 mg/ml)
Number of subjects: 47
Study 28025352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 47
Study 24211500 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 1312
Study 24211500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1312
Study 23743535 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading (LD group) - 3 mandatory doses of intravitreal bevacizumab
Number of subjects: 99
Study 23743535 — intervention group
Group type: COMPARATOR
Intervention: No Loading (NLD group) - no mandatory doses after baseline dose
Number of subjects: 99
Study 23743535 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading (LD group)
Number of subjects: 99
Study 23743535 — intervention group
Group type: COMPARATOR
Intervention: No Loading (NLD group)
Number of subjects: 99
Study 23743535 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading (LD group) and No Loading (NLD group)
Number of subjects: 99
Study 19934030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 1977
Study 19934030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 1977
Study 19934030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1977
Study 18940534 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of ezetimibe 10 mg/day and simvastatin (10, 20, or 40 mg/day) for 6 weeks
Number of subjects: 248
Study 18940534 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of ezetimibe 10 mg/day and simvastatin (40 mg/day) for 33 weeks
Number of subjects: 248
Study 18940534 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of ezetimibe 10 mg/day and simvastatin (10 or 20 mg/day) for 53 weeks
Number of subjects: 248
Study 16841664 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus Injection (AI)
Number of subjects: 67
Study 16841664 — intervention group
Group type: COMPARATOR
Intervention: Control group (dipyridamole and benazepril)
Number of subjects: 67
Study 12480116 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching by community pharmacists (3 drug coaching contacts and a 25-min take-home video)
Number of subjects: 148
Study 12480116 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 148
Study 10912701 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (Group A)
Number of subjects: 0
Study 10912701 — intervention group
Group type: COMPARATOR
Intervention: Abnormal control (Group B)
Number of subjects: 0
Study 10912701 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (Group C)
Number of subjects: 0
Study 1520059 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance plethysmography
Number of subjects: 83
Study 1520059 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression ultrasonography
Number of subjects: 83
Study 1520059 — intervention group
Group type: COMPARATOR
Intervention: Contrast venography
Number of subjects: 83
Study 6418670 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC‐containing artificial saliva (Group I, 40 patients)
Number of subjects: 137
Study 6418670 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating CMC‐ and mucin‐containing artificial saliva (Group II, 61 patients)
Number of subjects: 137
Study 6418670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucin‐containing artificial saliva (Group III, 36 patients)
Number of subjects: 137
Study 31296519 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical oncologists (MO) recommending thromboprophylaxis (TP)
Number of subjects: 1097
Study 31296519 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient factors (age, clinical setting, reason for admission, pre‐admission performance status, risk of bleeding)
Number of subjects: 1097
Study 31296519 — intervention group
Group type: COMPARATOR
Intervention: Palliative care (PC) physicians recommending thromboprophylaxis (TP)
Number of subjects: 1097
Study 31721495 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified socket shield technique (SST)
Number of subjects: 24
Study 31721495 — intervention group
Group type: COMPARATOR
Intervention: Conventional immediate implant placement
Number of subjects: 24
Study 29224641 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized feedback on adherence to prescribing evidence-based therapy for physicians; weekly home visits from community health workers for patients.
Number of subjects: 320
Study 29224641 — intervention group
Group type: COMPARATOR
Intervention: Regular updates on advances in HF management for physicians; monthly HF educational tip sheets for patients.
Number of subjects: 320
Study 27435412 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced invitation letter
Number of subjects: 796
Study 27435412 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation letter
Number of subjects: 796
Study 24558280 — intervention group
Group type: EXPERIMENTAL
Intervention: Amazing Self‐Care Race educational activity
Number of subjects: 86
Study 22565162 — intervention group
Group type: COMPARATOR
Intervention: 4 l Golytely single‐dosed (Go‐Si)
Number of subjects: 222
Study 22565162 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 l Golytely split‐dosed (Go‐Sp)
Number of subjects: 222
Study 22565162 — intervention group
Group type: EXPERIMENTAL
Intervention: 238 g MiraLAX in 64 oz of Gatorade single‐dosed (Mlax‐Si)
Number of subjects: 222
Study 22565162 — intervention group
Group type: EXPERIMENTAL
Intervention: MiraLAX/Gatorade split‐dosed (Mlax‐Sp)
Number of subjects: 222
Study 22565162 — intervention group
Group type: EXPERIMENTAL
Intervention: MiraLAX/Gatorade (Mlax)
Number of subjects: 222
Study 20731983 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant heavy drinkers (wives)
Number of subjects: 251
Study 20731983 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking couples (either partner)
Number of subjects: 251
Study 20731983 — intervention group
Group type: EXPERIMENTAL
Intervention: Wife as heavy drinker
Number of subjects: 251
Study 20731983 — intervention group
Group type: EXPERIMENTAL
Intervention: Husband as heavy drinker
Number of subjects: 251
Study 20731983 — intervention group
Group type: COMPARATOR
Intervention: Concordant abstainers/light drinkers
Number of subjects: 251
Study 17438555 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based group treatment (15 separate sessions for parents and children)
Number of subjects: 70
Study 17438555 — intervention group
Group type: COMPARATOR
Intervention: Routine counseling (two appointments for children)
Number of subjects: 70
Study 15960271 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.4 mg/ml with 6 microg/kg naloxone
Number of subjects: 59
Study 15960271 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg/ml morphine
Number of subjects: 59
Study 11922881 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoleamine (via tryptophan depletion) plus catecholamine (via alpha‐methyl‐paratyrosine administration) depletion
Number of subjects: 10
Study 11922881 — intervention group
Group type: COMPARATOR
Intervention: Indoleamine plus sham (via diphenhydramine administration) catecholamine depletion
Number of subjects: 10
Study 9704689 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor ramipril (2.5 to 20 mg/day)
Number of subjects: 29
Study 7653083 — intervention group
Group type: EXPERIMENTAL
Intervention: New compression device
Number of subjects: 133
Study 7653083 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (manual compression and pressure dressing)
Number of subjects: 133
Study 1758748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP at levels of 0, 3, 5, and 8 cm H2O
Number of subjects: 10
Study 1758748 — intervention group
Group type: COMPARATOR
Intervention: Baseline (without CPAP support)
Number of subjects: 10
Study 6758832 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 11
Study 6758832 — intervention group
Group type: COMPARATOR
Intervention: Oral terbutaline
Number of subjects: 11
Study 6758832 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 11
Study 6758832 — intervention group
Group type: COMPARATOR
Intervention: Oral salbutamol
Number of subjects: 11
Study 31307850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid surgically assisted rapid maxillary expansion (SARME)
Number of subjects: 20
Study 31307850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne (TB) surgically assisted rapid maxillary expansion (SARME)
Number of subjects: 20
Study 28888516 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted activities (AAA) for 10 minutes
Number of subjects: 48
Study 28888516 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no AAA)
Number of subjects: 48
Study 26349548 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of RV1 and OPV (monovalent, bivalent, or trivalent)
Number of subjects: 409
Study 26349548 — intervention group
Group type: COMPARATOR
Intervention: Staggered administration of RV1 and OPV (≥1 day apart)
Number of subjects: 409
Study 23349519 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (6.65 ± 1.66 mg/kg/d)
Number of subjects: 9
Study 23349519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 22548929 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 T magnetic resonance angiography (MRA)
Number of subjects: 0
Study 22548929 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 T magnetic resonance angiography (MRA)
Number of subjects: 0
Study 20428633 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/0.5g infused over 30 min
Number of subjects: 4
Study 20428633 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/1g infused over 30 min
Number of subjects: 4
Study 20428633 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX-SUL 0g/2g infused over 30 min
Number of subjects: 4
Study 20428633 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/0.5g infused over 3h
Number of subjects: 4
Study 20428633 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/1g infused over 3h
Number of subjects: 4
Study 17522235 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal and polychemotherapy therapy
Number of subjects: 0
Study 15203440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 g naltrexone implant
Number of subjects: 34
Study 15203440 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.4 g naltrexone implant
Number of subjects: 34
Study 12376047 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser light treatment (wavelength 810 nm, dose 4 J/cm2) in Group A
Number of subjects: 65
Study 12376047 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (quasi-laser therapy) in Group B
Number of subjects: 65
Study 12376047 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 65
Study 9807612 — intervention group
Group type: EXPERIMENTAL
Intervention: Komesaroff vaporizer at dial positions 1 or 1.5
Number of subjects: 0
Study 9807612 — intervention group
Group type: COMPARATOR
Intervention: Conventional vaporizer outside the circle for the first 10 minutes
Number of subjects: 0
Study 7570843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate
Number of subjects: 13
Study 7570843 — intervention group
Group type: COMPARATOR
Intervention: Aminosidine
Number of subjects: 13
Study 7570843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (after aminosidine)
Number of subjects: 13
Study 1971199 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg.kg‐1 IV lidocaine administered 1-4 minutes before intubation
Number of subjects: 125
Study 1971199 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone alone
Number of subjects: 125
Study 6771829 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg methylphenidate
Number of subjects: 9
Study 6771829 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 9
Study 6771829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30910480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinning on paraffin
Number of subjects: 126
Study 30910480 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct fixation in formalin
Number of subjects: 126
Study 30910480 — intervention group
Group type: COMPARATOR
Intervention: Cassette technique
Number of subjects: 126
Study 30910480 — intervention group
Group type: EXPERIMENTAL
Intervention: No handling method
Number of subjects: 126
Study 27561944 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 0
Study 27561944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 0
Study 26649538 — intervention group
Group type: EXPERIMENTAL
Intervention: Online rehabilitation with professional guidance by an audiologist
Number of subjects: 0
Study 24034834 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 G biopsy needles (Group A)
Number of subjects: 88
Study 24034834 — intervention group
Group type: COMPARATOR
Intervention: 18 G biopsy needles (Group B)
Number of subjects: 88
Study 21357882 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural therapy (CBT)
Number of subjects: 81
Study 21357882 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 81